This Pharma Company Is Preparing To Launch Its Lead Candidate

News Direct

Jul 25, 2024

–News Direct–

By Johnny Rice, Benzinga

Leonard Mazur, CEO and founder of Citius Pharmaceuticals (NASDAQ: CTXR), was recently interviewed by Benzinga.

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, stem cell therapy, and unique prescription products.

Mazur spoke about the exciting developments in the company’s assets, including the imminent launch of its first drug on the market.

Learn more here:

Featured photo by freestocks on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/this-pharma-company-is-preparing-to-launch-its-lead-candidate-252698575

YOU MAY ALSO LIKE

How PlusInvesting Prime AI Signals Indicator Enhances…

--News Direct--By Johnny Rice, BenzingaLeonard Mazur, CEO and founder of Citius Pharmaceuticals (NASDAQ: CTXR), was recently interviewed by Benzinga.Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical…

read more

Investor Releases Satirical Video Calling for Reid…

--News Direct--By Johnny Rice, BenzingaLeonard Mazur, CEO and founder of Citius Pharmaceuticals (NASDAQ: CTXR), was recently interviewed by Benzinga.Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical…

read more

ACTIVATE ACCELERATES US EXPANSION WITH 50 NEW…

--News Direct--By Johnny Rice, BenzingaLeonard Mazur, CEO and founder of Citius Pharmaceuticals (NASDAQ: CTXR), was recently interviewed by Benzinga.Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical…

read more